Posts Archive

NCT04891809: Phase 2 - Isatuximab in Combination With Rd Compared to Rd in Elderly Patients (Aged ≥70 Years) With NDMM As optimal...

What are Multiple myeloma defining events? International Myeloma Working Group - SLiM-CRAB Criteria What are myeloma defining events? ...

NCT04835129: Phase 2: Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma (IMPEDE)...

NCT04824794: Phase 1/2: GEN3014 Safety Trial in Relapsed or Refractory Hematologic Malignancies GEN3014 Safety Trial in Relapsed or...

NCT04754945: Phase 1: Isatuximab as Upfront Therapy for the Treatment of High Risk AL Amyloidosis NCT04754945: Phase 1: Isatuximab as...

NCT04786028: Phase 2 - A Study of Isatuximab Added to Standard CyBorD Induction and Lenalidomide Maintenance Treatments in ND-TEMM A...

NCT04776395 Iberdomide Alone or in Combination With Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple...

Multiple Myeloma Research Foundation THE MMRF - The Path to Precision Medicine in Multiple Myeloma THE MMRF - The Path to Precision...

KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma Blood Cancer J; 2021...

SABLe NCT04717700: Phase 2: Selinexor With Alternating Bortezomib or Lenalidomide Plus Dexamethasone in TIE Newly Diagnosed MM Patients...

MCRT Webcast - Myeloma Crowd Round Table Myeloma Crowd Round Tables program MCRT Webcast Apr 10, 2021 Overview of BCMA & Other Targets in...

MAGNETISMM-2 NCT04798586: Phase 1: MAGNETISMM-2: Study of Elranatamab (PF-06863135) in Japanese Participants With Multiple Myeloma...

NCT04722146: Phase 1b - Teclistamab With Other Anticancer Therapies in Participants With Myeloma Newly Diagnosed Multiple Myeloma...

NCT04850846: Phase 2: Investigation of Metformin for the Prevention of Progression of Precursor Multiple Myeloma Investigation of...

THE MMRF - Managing Myeloma Resource Brochure Click here to download Learn more: Multiple Myeloma Research Foundation Education Programs...

THE MMRF - Multiple Myeloma Treatment Overview Click here to download Learn more: Multiple Myeloma Research Foundation Education Programs...

NCCN GUIDELINES FOR PATIENTS: Immunotherapy Side Effects: CAR T-Cell Therapy https://www.nccn.org/patients/guidelines/content/PDF/immunot...

NCT04892446: Phase 2: Study of Magrolimab Combinations in Participants With Relapsed/Refractory Multiple Myeloma NCT04892446: Phase 2:...

NUTRIVENTION Study NCT04920084: A Study of a Plant-Based Diet in People With Monoclonal Gammopathy of Undetermined Significance (MGUS) or...